In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2416-2419

  Schwalbe, Richard S ^a,b,d   Mcintosh, Angela C ^a   Qaiyumi, Sadaf ^a   Johnson, Judith A ^a,b   Johnson, Robert J ^a,b   Furness, Kathleen M ^c   Holloway, William J ^c   Steele Moore, Lynn ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL CENTER OF DELAWARE   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; METICILLIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; HOSPITAL INFECTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029820318     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2416     Document Type: Article

References (18)

1. Arthur, M., and P. Courvalin. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37:1563-1571.
2. Collins, L. A., G. J. Malanoski, G. M. Eliopoulos, C. B. Wennersten, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 37:598-601.
3. Facklam, R. R., and M. D. Collins. 1989. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27:731-734.
4. Hackbarth, C. J., and H. F. Chambers. 1989. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob. Agents Chemother. 33:995-999.
5. Hayden, M. K., G. M. Trenholme, J. E. Schultz, and D. F. Sahm. 1993. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J. Infect. Dis. 167:1224-1227.
6. Inoue, M., R. Okamoto, T. Okubo, K. Inoue, and S. Mitsuhashi. 1992. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. J. Antimicrob. Chemother. 30(Suppl. A):45-51.
7. Johnson, J. A., Z. Li, S. Qaiyumi, T. Harrison, J. G. Morris, Jr., R. J. Johnson, and R. Schwalbe. 1995. Distribution of vancomycin resistant enterococci (VRE) genotypes differs in ill versus colonized patients, abstr. E37, p. 92. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Jones, R. N., H. S. Sader, M. E. Erwin, S. C. Anderson, and the Enterococcus Study Group. 1995. Emerging multiply resistant enterococci among clinical isolates. Diagn. Microbiol. Infect. Dis. 21:85-93.
9. Leclercq, R., L. Nantas, C.-J. Soussy, and J. Duval. 1992. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolidc-lincosamide-strepto-gramin antibiotics. J. Antimicrob. Chemother. 30(Suppl. A):67-75.
10. Low, D. E., A. McGeer, and R. Poon. 1989. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob. Agents Chemother. 33:585-588.
11. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - third edition; approved standard. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing. M100-S6: M7-A3, Table 2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Nicas, T. I., and R. D. G. Cooper. 1995. Activity of novel semi-synthetic glycopeptides against vancomycin-resistant enterococci, abstr. 560. In Program Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases, Vienna, Austria.
14. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. L. Snyder, R. E. Stratford, and R. D. G. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
15. Schaberg, D. R., D. H. Culver, and R. P. Gaynes. 1991. Major trends in microbial etiology of nosocomial infection. Am. J. Med. 91(Suppl. 3B):72S-75S.
16. Schwalbe, R. S., W. J. Ritz, P. R. Verma, E. A. Barranco, and P. H. Gilligan. 1990. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J. Infect. Dis. 161:45-51.
17. Steele-Moore, L., A. Macintosh, K. Furness, W. Holloway, and R. S. Schwalbe. 1996. In vitro activity of an investigational glycopeptide antibiotic LY333328, abstr. A-59, p. 143. In Abstracts of the 96th General Meeting of The American Society for Microbiology 1996. American Society for Microbiology, Washington, D.C.
18. Venuti, E., J. Dean, and H. Fraimow. 1994. Characterization of vancomycin resistant enterococci (VRE) by polymerase chain reaction (PCR) for vanB1 and vanB2, abstr. C-212, p. 527. In Abstracts of the 94th General Meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington, D.C.